Sangamo Therapeutics/SGMO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Ticker

SGMO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alexander Macrae

Employees

405

Headquarters

Richmond, United States

SGMO Metrics

BasicAdvanced
$117M
Market cap
-
P/E ratio
-$1.86
EPS
1.35
Beta
-
Dividend rate
$117M
1.34991
$1.67
$0.29
1.9M
1.706
-115.20%
-167.24%
-139.17%
6.244
2.028
2.066
-92.22%
-126.90%
14.24%

What the Analysts think about SGMO

Analyst Ratings

Majority rating from 9 analysts.
Buy

SGMO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-12,250.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$400K
-80.00%
Net income
-$49M
-18.60%
Profit margin
-12,250.00%
306.98%

SGMO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 26.32%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.59
-$0.34
-$0.27
-
Expected
-$0.34
-$0.32
-$0.26
-$0.21
-$0.15
Surprise
92.73%
84.37%
32.70%
26.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sangamo Therapeutics stock?

Sangamo Therapeutics (SGMO) has a market cap of $117M as of June 15, 2024.

What is the P/E ratio for Sangamo Therapeutics stock?

The price to earnings (P/E) ratio for Sangamo Therapeutics (SGMO) stock is 0 as of June 15, 2024.

Does Sangamo Therapeutics stock pay dividends?

No, Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Sangamo Therapeutics dividend payment date?

Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders.

What is the beta indicator for Sangamo Therapeutics?

Sangamo Therapeutics (SGMO) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Sangamo Therapeutics stock price target?

The target price for Sangamo Therapeutics (SGMO) stock is $3.5, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Sangamo Therapeutics stock

Buy or sell Sangamo Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing